Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
Introduction: Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has proved to be an effective treatment for metastatic melanoma, even in patients failing anti-PD-1 blockade. Nevertheless, progression is observed in a substantial subgroup of patients following an initial objective res...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-02-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/2/e010575.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206885945442304 |
|---|---|
| author | Rikke Andersen Troels Holz Borch Eva Ellebaek Inge Marie Svane Helle Westergren Hendel Kasper Madsen |
| author_facet | Rikke Andersen Troels Holz Borch Eva Ellebaek Inge Marie Svane Helle Westergren Hendel Kasper Madsen |
| author_sort | Rikke Andersen |
| collection | DOAJ |
| description | Introduction: Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has proved to be an effective treatment for metastatic melanoma, even in patients failing anti-PD-1 blockade. Nevertheless, progression is observed in a substantial subgroup of patients following an initial objective response to treatment with TILs. These patients might benefit from additional consolidating treatment before clinical progression, but thus far, it is not possible to identify this subgroup of patients prone to progress. In this study the predictive value of early metabolic response after TIL therapy is explored.Materials and methods: 60 patients treated with TIL therapy in 4 different clinical trials and with available [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography-CT (FDG-PET/CT) scans at baseline and at least one follow-up scan 6–8 weeks and/or 12–16 weeks post-TIL infusion were included.Results: Obtaining complete metabolic response (CMR) was associated with significantly superior median overall survival (mOS) compared with not obtaining CMR (p<0.0001). Of particular interest, metabolic response divided RECIST partial responders (22 patients) into two groups with significantly different clinical outcomes. Neither mOS (range 32.2–149.8+) nor median progression-free survival (mPFS; range 20.7–123.4+) were reached for patients with partial response (PR)/CMR (10 patients), whereas patients with PR/non-CMR (12 patients) had a mOS of 28.7 months (p=0.0016) and a mPFS of 7.8 months (p<0.0001).Overall, not achieving a CMR was associated with a short mPFS of 3.2 months, and 97.9% (47/48) of all patients in this group progressed within 12 months.Conclusion: In conclusion, early CMR is a strong predictor of long-term survival after TIL therapy in metastatic melanoma patients. Furthermore, FDG-PET/CT scans appear superior to CT scans for providing early prognostic information after TIL therapy in melanoma and can be used to tailor patient-specific management and follow-up strategies. |
| format | Article |
| id | doaj-art-8fca229d51b74ca2b775c2bf5243bdbd |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-8fca229d51b74ca2b775c2bf5243bdbd2025-02-07T04:50:09ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-02-0113210.1136/jitc-2024-010575Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytesRikke Andersen0Troels Holz Borch1Eva Ellebaek2Inge Marie Svane3Helle Westergren Hendel4Kasper Madsen5Department of Oncology, Herlev Hospital, Herlev, DenmarkNational Center for Cancer Immune Therapy, Herlev Hospital, Herlev, DenmarkNational Center for Cancer Immune Therapy, Herlev Hospital, Herlev, DenmarkNational Center for Cancer Immune Therapy, Herlev Hospital, Herlev, DenmarkDepartment of Clinical Physiology and Nuclear Medicine, Herlev Hospital, Herlev, DenmarkNational Center for Cancer Immune Therapy, Herlev Hospital, Herlev, DenmarkIntroduction: Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has proved to be an effective treatment for metastatic melanoma, even in patients failing anti-PD-1 blockade. Nevertheless, progression is observed in a substantial subgroup of patients following an initial objective response to treatment with TILs. These patients might benefit from additional consolidating treatment before clinical progression, but thus far, it is not possible to identify this subgroup of patients prone to progress. In this study the predictive value of early metabolic response after TIL therapy is explored.Materials and methods: 60 patients treated with TIL therapy in 4 different clinical trials and with available [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography-CT (FDG-PET/CT) scans at baseline and at least one follow-up scan 6–8 weeks and/or 12–16 weeks post-TIL infusion were included.Results: Obtaining complete metabolic response (CMR) was associated with significantly superior median overall survival (mOS) compared with not obtaining CMR (p<0.0001). Of particular interest, metabolic response divided RECIST partial responders (22 patients) into two groups with significantly different clinical outcomes. Neither mOS (range 32.2–149.8+) nor median progression-free survival (mPFS; range 20.7–123.4+) were reached for patients with partial response (PR)/CMR (10 patients), whereas patients with PR/non-CMR (12 patients) had a mOS of 28.7 months (p=0.0016) and a mPFS of 7.8 months (p<0.0001).Overall, not achieving a CMR was associated with a short mPFS of 3.2 months, and 97.9% (47/48) of all patients in this group progressed within 12 months.Conclusion: In conclusion, early CMR is a strong predictor of long-term survival after TIL therapy in metastatic melanoma patients. Furthermore, FDG-PET/CT scans appear superior to CT scans for providing early prognostic information after TIL therapy in melanoma and can be used to tailor patient-specific management and follow-up strategies.https://jitc.bmj.com/content/13/2/e010575.full |
| spellingShingle | Rikke Andersen Troels Holz Borch Eva Ellebaek Inge Marie Svane Helle Westergren Hendel Kasper Madsen Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes Journal for ImmunoTherapy of Cancer |
| title | Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes |
| title_full | Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes |
| title_fullStr | Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes |
| title_full_unstemmed | Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes |
| title_short | Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes |
| title_sort | complete metabolic response as early predictor of long term efficacy after adoptive t cell therapy using tumor infiltrating lymphocytes |
| url | https://jitc.bmj.com/content/13/2/e010575.full |
| work_keys_str_mv | AT rikkeandersen completemetabolicresponseasearlypredictoroflongtermefficacyafteradoptivetcelltherapyusingtumorinfiltratinglymphocytes AT troelsholzborch completemetabolicresponseasearlypredictoroflongtermefficacyafteradoptivetcelltherapyusingtumorinfiltratinglymphocytes AT evaellebaek completemetabolicresponseasearlypredictoroflongtermefficacyafteradoptivetcelltherapyusingtumorinfiltratinglymphocytes AT ingemariesvane completemetabolicresponseasearlypredictoroflongtermefficacyafteradoptivetcelltherapyusingtumorinfiltratinglymphocytes AT hellewestergrenhendel completemetabolicresponseasearlypredictoroflongtermefficacyafteradoptivetcelltherapyusingtumorinfiltratinglymphocytes AT kaspermadsen completemetabolicresponseasearlypredictoroflongtermefficacyafteradoptivetcelltherapyusingtumorinfiltratinglymphocytes |